Beside its benefit as a marker of prostate cancer progression, it was shown that the degree of expression of this protein was related to outcome after radical prostatectomy.31 Whilst strong expression was associated with recurrence of tumor after surgery in a third of patients, weak EZH2 staining was found in only 9% of individuals with clinical failure. The gene discussed is EZH2; the disease is prostate cancer.